At what enterprise value was AENOVA GROUP acquired in 2012?

During the acquisition of AENOVA GROUP by BC PARTNERS in 2012, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of AENOVA GROUP when it was acquired by BC PARTNERS?

The estimated EV/EBITDA multiple for AENOVA GROUP is in the range of 5x - 12x.

When was AENOVA GROUP acquired by BC PARTNERS?

AENOVA GROUP was acquired by BC PARTNERS in 2012.

What was the revenue of AENOVA GROUP at the time of the deal?

The revenue of AENOVA GROUP at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of AENOVA GROUP during the acquisition?

AENOVA GROUP's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the AENOVA GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the AENOVA GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.bcpartners.com/news/bc-partners-to-acquire-aenova-group-from-bridgepoint/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaAENOVA GROUP

08/2012

AENOVA GROUP acquired by BC PARTNERS

GERMANY Life Sciences / Pharma & Biotech / CDMO EV 300M - 700M EUR

Context

BC Partners have signed a definitive agreement to acquire a majority stake in the Aenova Group from the European private equity firm Bridgepoint. This secondary LBO marks the end of Bridgepoint’s ownership period, which began in 2005, during which Aenova was transformed into one of Europe’s leading CDMOs. The current management team, led by CEO Heiner Hoppmann and CFO Frank Elsen, will remain at the helm to lead the next phase of the company's development. The strategic rationale for the acquisition is focused on leveraging Aenova’s superb market positioning to drive both organic and inorganic growth. BC Partners intends to utilize the group as a platform for further acquisitions to broaden its service range and enhance its competitive standing in international markets. For Aenova, the partnership with BC Partners provides the necessary capital to expand its "customer-centric" strategy and invest in innovative manufacturing technologies.

AENOVA GROUP, which reported an EBITDA margin of in 2012, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

The Aenova Group is a leading global contract development and manufacturing organization (CDMO) serving the pharmaceutical and healthcare industries. Headquartered in Starnberg, Germany, the company operates as a comprehensive "one-stop shop" for the development, production, and packaging of a vast array of drug products. Its technical capabilities span all common dosage forms (including solid, semi-solid, liquid, sterile, and non-sterile applications) across both human and animal health. The group is particularly noted for its expertise in handling diverse active ingredient classes, ranging from standard pharmaceuticals to specialized food supplements, with high-containment capabilities (OEB 1 to 5). Its business model focuses on providing end-to-end supply chain services to global pharma companies, supported by a network of 14 specialized manufacturing sites across Europe and the USA. By combining operational excellence in conventional manufacturing with advanced technology platforms, Aenova addresses the complex regulatory and technical requirements of the modern pharmaceutical market, positioning itself as one of the ten largest CDMOs worldwide.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2012

2011

Other operations with AENOVA GROUP

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2024	KÜHNE HOLDING	AENOVA GROUP	GERMANY	CDMO

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AENOVA GROUP by BC PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: bc partners